Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0598934 (tumor growth)
 58,965 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The survival time of animals, inhibition of the incorporation of thymidine-[6-3H] (3H-TdR) into DNA, and histopathological observation were made after the injection of Mitomycin-C, Bleomycin, cyclophosphamide, Daunomycin, Actinomycin-D, or 5-fluorouracil into mice transplanted with sarcoma-180 to their liver, kidney, and lung. The most prolonged survival time was obtained by the injection with cyclophosphamide and a moderate prolonged survival by Bleomycin and Actinomycin-D. In the case of 5-fluorouracil and Daunomycin, there were extreme variations in the survival time depending on the site of tumor growth. Cyclophosphamide and 5-fluorouracil showed greater and longer lasting inhibition of the incorporation of 3H-TdR into DNA of the tumor tissue, whereas the remaining agents caused transient inhibition on the tumor tissue. Inhibitory ratio and duration of the incorporation of 3H-TdR into DNA of normal site of the tissue of tumor-bearing organ were found to be more increased or almost the same compared with those of the tumor tissue. The most rapid recovery of the incorporation of 3H-TdR into DNA was observed in the small intestine among various organs and tumor in any treatment groups. From the histopathological observation, the degree of tumor cell damage by the agent was almost in agreement with inhibition of the incorporation of 3H-TdR up to 72 hr after the treatment.
 ...
PMID:Effect of antitumor agents on sarcoma-180 tumor cells transplanted to liver, kidney, and lung. 5 69

Based on the experimental results that operative stress of thoracotomy or laparothoracotomy has enhanced tumor growth remarkably in rats compared with laparotomy, a new combined treatment with by-pass operation, irradiation and immunochemotherapy was investigated in 39 advanced thoracic esophageal cancer patients. At by-pass operation, abdominal esophagus was divided and its proximal stump was closed immediately. Cervical esophagus was then divided and its distal stump was pulled out to the right supraclavicular region to make outer fistula. Thus, anticancer drug was poured into the esophagus through outer fistula very easily just before irradiation and then irradiation was performed under the condition that the lesion was immersed in the drugs. As anticancer agent, Mitomycin-C, 5-Fluorouracil or Bleomycin was given alternately. Lately, the combination of 5-Fluorouracil and Vitamin A was preferably used. The changes of immunological parameters and the survival after the onset of treatment was reported.
 ...
PMID:Combined treatment with by-pass operation, irradiation and immunochemotherapy for advanced thoracic esophageal cancer. 8 30

Tumor-inhibitory effect of combined use of mitomycin-C and streptococcal preparation (OK-432) or yeast cell wall (YCW) was examined. Twenty-four hours after intraperitoneal inoculation of Ehrlich carcinoma cells, combination therapy was carried out and tumor growth was observed for 40 days. About one-half of mice treated with yeast cell wall at a single dose of 1 mg survived free of tumor. Mitomycin-C at a single dose of 2 microgram was not effective. However, in combination with yeast cell wall, tumor suppression was observed in 70% of the mice. This tumor-inhibitory effect was enhanced by subsequent treatment with OK-432 or yeast cell wall. When these materials were injected separately or in combination with mitomycin-C, the number of peritoneal exudate cells increased about 3 to 6 times after 3 days and these cells exhibited cytotoxic effect on tumor cells. Hemagglutinating antibody to sheep erythrocytes was hardly affected by the combination therapy.
 ...
PMID:Antitumor effect of combined use of OK-432 and yeast cell wall with mitomycin-C in mice. 59 Jun 87

For the purpose of predicting the effect of carcinostatic agents on tumor-bearing host in vitro, a sensitivity test of a drug in tumor bearers was developed. This test is based on the change in the specific activity of acid phosphatase of individual tumor and liver tissue, and the difference in them was used as an indicator of effectiveness. The value was called the "effective value." The present papar is concerned with the relationship between the effective value and effectiveness of the agents in rodents and man. The results showed that the effective value became higher with increasing concentration of Mitomycin-C incubated with tumor and liver tissues. The survival time of Ehrlich carcinoma-bearing mice, which were given Mitomycin-C intraperitoneally, was longer and increase in the dose of Mitomycin-C. In ascitic or subcutaneous form of Ehrlich carcinoma, AH-130, and Yoshida sarcoma, the effective value was parallel with the survival time of or the inhibition of tumor growth in tumor-bearing animals treated with Mitomycin-C. In 25 patients with gastric carcinoma treated with Mitomycin-C, the postoperative survival time was more closely correlated with the effective value calculated by the titers of both tumor and liver than the value of tumor alone.
 ...
PMID:Predication of the effect of carcinostatic agents on tumor-bearing host by the sensitivity test using acid phosphatase activity in vitro. 101 80

The effect of antitumor agents (lentinan, PS-K, Mitomycin-C, 6-mercaptopurine, etc.) on the antitumor delayed hypersensitivity reaction (DHR) measured by the foot-pad test was compared with their effect on tumor growth in ddY mice with Ehrlich tumor. These agents all inhibited growth of Ehrlich carcinoma. Lentianan and PS-K enhanced the antitumor DHR, but Mitomycin-C and 6-mercaptopurine did not. By plotting the effect of agents on the anti-tumor DHR against these effects on tumor weight, host-mediated antitumor agents could be differentiated from mitotic poisons. Attempts to distinguish these two types of agents by the same method using a syngeneic tumor system were unsuccessful.
 ...
PMID:Differentiation of host-mediated antitumor agents from mitotic posons by the antitumor foot-pad reaction in Ehrlich carcinoma-ddY mouse system. 101 84

HeLa cells were heterotransplanted to nude mice and their response to some of antitumor agents was investigated. HeLa cell-tumor readily grew in nude mice and no regression was observed. Metastases to the lung and other organs were noticed in some of the animals. Histopathological examination revealed that the tumor retained the original characteristics of human epidermoid carcinoma. Standardization of HeLa cell-tumor in nude mice for the screening and evaluation of antitumor chemotherapeutics was attempted. Marked inhibition of tumor growth was observed with lower doses of Mitomycin-C, 5-fluorouracil, Adriamycin, and Bleomycin. The tumor regression was observed with high doses of Mitomycin-C, Adriamycin, and 5-fluorouracil. However, cyclophosphamide, cytosine arabinoside, and daunorubicin had little effect on the tumor growth. Complete regression was not obtained with any of the test agents and active regrowth took place even with the most effective compound. Considerable variation in the effect on tumor growth was observed among the test compounds, while histopathological findings were much alike; few mitotic figures, vacuolization, and pyknosis were main changes in tumor cells, and large foci of necrosis and hemorrhage were present in the degenerative areas. The regrowth was initiated around the capillaries in the necrotic tumor tissue.
 ...
PMID:HeLa cell-tumor in nude mice and its response to antitumor agents. 103 Jun 74

This experimental study was undertaken to evaluate the effectiveness of a large-dose intratumoral administration of OK-432, which has already been found to be effective when combined with Mitomycin-C, 5-fluorouracil, and cytosine arabinoside, and/or small-dose of OK-432 in clinical use. Large-dose of OK-432 was administered intratumorally 15 days after the subcutaneous inoculation of 2.5 X 10(6) Ehrlich carcinoma cells. At the same time, 2.5 X 10(6) tumor cells were re-challenged intraperitoneally. A combined treatment with a small-dose of OK-432 and Mitomycin-C, cyclophosphamide, or 5-fluorouracil was also made. As a large-dose of OK-432, three-dose regimen of 1,000, 500, and 100 KE/kg was tested. As a small-dose of OK-432, 4 consecutive daily intramuscular injection of 50 KE/kg was examined. From the results obtained the initial intratumoral administration of a large-dose of OK=432 was found to be beneficial for the following combined treatment with a small-dose of OK-432 and Mitomycin-C or cyclophosphamide. The change of phytohemagglutinin (PHA) responsiveness of spleen cells after intratumoral injection of a large-dose of OK-432 was investigated in mice. These results indicated a decrease of PHA responsiveness of spleen cells according to the tumor growth. The intratumoral large-dose administration of OK-432 suggested inhibition of the decrease in PHA responsiveness. The most effective and suitable dose in this experiment was found to be 500 KE/kg in the three-dose regimen.
 ...
PMID:Experimental study on the effect of large-dose intratumoral OK-432 administration in mice. 126 51

TT-1 cells, a cell line derived from pancreatic carcinoma in 1962, were tested in nude mice (BALB/c nu/nu) for their tumorigenicity and histopathological features following cell injection. Moreover, an experimental chemotherapy of TT-1-cell-induced tumors in nude mice and attempts of extracting TT-1 tumor-associated antigens were made. The tumorigenicity was measured by subcutaneous inoculation of TT-1 cells in the back of nude mice. The 50% tumor-producing dose (TPD50) for 3-wk and 5-wk old nude mice were 4.7 X 10(4) and 2.4 X 10(5) cells respectively. When 5 TPD50 of TT-1 cells were inoculated subcutaneously into 3-wk old mice, initially cells were found in the subcutaneous space of the inoculated site, then gradually growing into colonies which could be clearly demonstrated microscopically 6 days after inoculation, though by that time tumor was not perceivable nor palpable. Mitomycin-C and fluoro-uracil were administered 2 days after TT-1 cell inoculation. It was found that 5 doses of 8 microgram mitomycin-C and 0.25 mg fluoro-uracil administered intravenously were effective to prevent the nude mice inoculated with 5 TPD50 from tumor formation. However, if these two drugs were injected 3 weeks later, tumor growth was suppressed only by the first 4 doses of drugs but not thereafter. Immune sera were prepared by immunizing rabbits and mice with 3 M KCl extract of nude mouse-grown tumors. Nude mouse serum and subcutaneous tissue antigens were present in the tumor extract and showed strong antigenicity.
 ...
PMID:Histopathological changes and experimental chemotherapy of TT-1 cell-induced tumor in nude mice. 704 32